- 92Bio revives a T cell engager it had transferred to AmgenA small California startup is reviving an experimental T cell engager that its scientists originally developed but had handed off to Amgen years ago. After repeatedly saying it would bring the drug…Endpoints · 25d ago↗ source
- Angitia ends Phase 3 in disc disease; Abivax targets $800M on colitis data🩻 Angitia Biopharmaceuticals drops Phase 3: The US and China biotech terminated a late-stage trial of AGA111 in patients with degenerative disc disease who had a lumbar interbody fusion, according…Endpoints · 25d ago↗ source
- FDA says Zyn can market its pouches as safer than cigarettesThe influence of the alcohol industry on policy, AI Claude for scientists, and more health news from Morning RoundsSTAT